Filtered By:
Specialty: Drugs & Pharmacology
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 546 results found since Jan 2013.

Development of Biomembrane-mimetic Nanoparticles for the Treatment of Ischemic Stroke
Yakugaku Zasshi. 2021;141(9):1071-1078. doi: 10.1248/yakushi.21-00114.ABSTRACTIncrease in vascular permeability of the blood-brain barrier (BBB) is a distinct pathology following ischemic stroke. In previous studies, we demonstrated that liposomal drug delivery system (DDS)-based delivery of neuroprotectants is useful for treating cerebral ischemia/reperfusion injury. Additionally, our previous studies reported that combination therapy with liposomal fasudil plus tissue plasminogen activator (t-PA), a thrombolytic agent, brings about decrease in the risk of t-PA-derived cerebral hemorrhage and prolong the therapeutic time ...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - September 2, 2021 Category: Drugs & Pharmacology Authors: Tatsuya Fukuta Source Type: research

Tenecteplase use in the management of acute ischemic stroke: Literature review and clinical considerations
CONCLUSION: Current clinical evidence shows that tenecteplase is not inferior to alteplase for the treatment of ischemic stroke and suggests that tenecteplase may have a superior safety profile. Furthermore, tenecteplase also has practical advantages in terms of its administration. This can potentially lead to a decrease in medication errors and improvement in door to thrombolytic time.PMID:35020806 | DOI:10.1093/ajhp/zxac010
Source: American Journal of Health-System Pharmacy : AJHP - January 12, 2022 Category: Drugs & Pharmacology Authors: Kirubel Hailu Chad Cannon Sarah Hayes Source Type: research

A practice game changer: Impact of tenecteplase for acute ischemic stroke in a multicenter quality improvement project
CONCLUSION: Institutions can safely transition from alteplase to tenecteplase as a thrombolytic of choice for AIS.PMID:35037028 | DOI:10.1093/ajhp/zxab482
Source: American Journal of Health-System Pharmacy : AJHP - January 17, 2022 Category: Drugs & Pharmacology Authors: Lydia Noh Felix Pham Lara Haddad Theresa Burkhard Laurie Paletz Marco Pech Maya Lewis Vicki Manoukian Konrad H Schlick Shlee Song Source Type: research

Discovery of anti-stroke active substances in Guhong injection based on multi-phenotypic screening of zebrafish
Biomed Pharmacother. 2022 Sep 23;155:113744. doi: 10.1016/j.biopha.2022.113744. Online ahead of print.ABSTRACTIschemic stroke is a leading cause of death worldwide, and it remains an urgent task to develop novel and alternative therapeutic strategies for the disease. We previously reported the positive effects of Guhong injection (GHI), composed of safflower extract and aceglutamide, in promoting functional recovery in ischemic stroke mice. However, the active substances and pharmacological mechanism of GHI is still elusive. Aiming to identify the active anti-stroke components in GHI, here we conducted a multi-phenotypic s...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 26, 2022 Category: Drugs & Pharmacology Authors: Yule Wang Huimin Wu Hongda Sheng Yingchao Wang Xuecai Li Yi Wang Lu Zhao Source Type: research

RCT: Endovascular treatment for acute ischaemic stroke
Source: NEJM Area: News A study, published in New England Journal of Medicine, compares the clinical efficacy of endovascular treatment with systemic intravenous thrombolytic therapy in patients with ischaemic stroke.   The study randomly assigned 362 patients with acute ischemic stroke, within 4.5 hours after onset, to endovascular therapy (intra-arterial thrombolysis with recombinant tissue plasminogen activator [t-PA], mechanical clot disruption or retrieval, or a combination of these approaches) (181 patients) or intravenous t-PA (181 patients). Treatments were to be given as soon as possible after randomisat...
Source: NeLM - News - February 8, 2013 Category: Drugs & Pharmacology Source Type: news

Reperfusion Therapies in Acute Ischemic Stroke.
Authors: Yeo LL, Tan BY, Yee W, Amit K, Sharma VK Abstract Acute Ischemic stroke (IS) remains a leading cause of mortality and long-term disability. Owing to the time-constraints, only a fraction of acute IS patients receive the established and approved thrombolytic therapy and a sizeable proportion of acute IS stroke survivors remain permanently disabled. Rapid advances in various recanalization strategies have aimed at improving functional outcome and reducing mortality. Existing literature on various treatment approaches, including the evolution of various thrombolytic agents and interventional devices is presen...
Source: Recent Patents on CNS Drug Discovery - July 3, 2015 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research

Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry
ConclusionsThe quality of warfarin treatment was strongly associated with the risk of stroke and the prognosis of AF patients. Patient outcomes continued to improve with increasing TTR values up to a TTR ≥80%; therefore, the target for the TTR should exceed 80% instead of the traditional range of at least 60–70%. Copyright © 2017 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - February 28, 2017 Category: Drugs & Pharmacology Authors: Mika Lehto, Jussi Niiranen, Pasi Korhonen, Juha Meht älä, Houssem Khanfir, Fabian Hoti, Riitta Lassila, Pekka Raatikainen Tags: Original Report Source Type: research

Blood-Brain Barrier Protection as a Therapeutic Strategy for Acute Ischemic Stroke
AbstractThe blood-brain barrier (BBB) is a vital component of the neurovascular unit (NVU) containing tight junctional (TJ) proteins and different ion and nutrient transporters which maintain normal brain physiology. BBB disruption is a major pathological hallmark in the course of ischemic stroke which is regulated by the actions of different factors working at different stages of cerebral ischemia including matrix metalloproteinases (MMPs), inflammatory modulators, vesicular trafficking, oxidative pathways, and junctional-cytoskeletal interactions. These components interact further to disrupt maintenance of both the parac...
Source: The AAPS Journal - May 8, 2017 Category: Drugs & Pharmacology Source Type: research